Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer

Oncology (Williston Park). 2018 Oct 15;32(10):513-5.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aminopyridines / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Aromatase Inhibitors / administration & dosage
  • Benzimidazoles / therapeutic use
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • Carcinoma, Lobular / drug therapy*
  • Carcinoma, Lobular / metabolism
  • Carcinoma, Lobular / secondary
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / metabolism
  • Colonic Neoplasms / secondary
  • Cyclin-Dependent Kinase 4 / antagonists & inhibitors*
  • Cyclin-Dependent Kinase 6 / antagonists & inhibitors*
  • Female
  • Humans
  • Letrozole / administration & dosage
  • Middle Aged
  • Neoplasm Metastasis
  • Piperazines / administration & dosage
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / therapeutic use
  • Purines / therapeutic use
  • Pyridines / administration & dosage
  • Receptor, ErbB-2 / metabolism
  • Receptors, Estrogen / metabolism
  • Receptors, Progesterone / metabolism

Substances

  • Aminopyridines
  • Aromatase Inhibitors
  • Benzimidazoles
  • Piperazines
  • Protein Kinase Inhibitors
  • Purines
  • Pyridines
  • Receptors, Estrogen
  • Receptors, Progesterone
  • abemaciclib
  • Letrozole
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Cyclin-Dependent Kinase 4
  • Cyclin-Dependent Kinase 6
  • palbociclib
  • ribociclib